FDA expands use of Zoryve to include young children with plaque psoriasis

FDA expands use of Zoryve to include young children with plaque psoriasis. The U.S.

A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.

Trechos de apoio da pauta: The U.S. Food and Drug Administration has approved an expanded indication for Zoryve (roflumilast) cream, 0.3%, for the topical treatment of plaque psoriasis in patients ages 2 and older.

• Ponto de atenção: expands.
• Ponto de atenção: zoryve.
• Ponto de atenção: include.

Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.